Evidence Level
Apigenin is a bioactive flavonoid with diverse pharmacological effects. At the molecular level, Avallone et al. (2000) demonstrated that apigenin binds to the GABA-A benzodiazepine site, which explains its sedative and anxiolytic properties. Additionally, Escande et al. (2013) identified apigenin as a CD38 inhibitor, which enhances NAD+ levels, suggesting potential benefits for metabolic health.
Preclinical studies highlight apigenin's anti-inflammatory and antioxidant effects. Rahimi et al. (2022) conducted a systematic review of 14 preclinical studies, showing that apigenin significantly reduces inflammatory markers such as NF-κB, IL-1β, IL-6, and TNF-α, while also decreasing oxidative stress in lung injury models. Similarly, Wang et al. (2024) performed a meta-analysis of five studies involving 226 rats, finding that apigenin reduces inflammation and oxidative stress in acute lung injury models.
In the context of cancer, Singh et al. (2022) reviewed 25 animal studies and found that apigenin significantly reduces tumor volume, weight, number, and load across various cancers without affecting body weight. Furthermore, Ahmadzadeh et al. (2024) analyzed 39 preclinical studies and concluded that apigenin decreases cell viability and tumor size in colorectal adenocarcinoma models, suggesting its potential as an adjuvant therapy.
Despite these promising findings, human randomized controlled trials (RCTs) with purified apigenin are limited. The evidence primarily来源于 chamomile extract studies, where apigenin is considered the main active compound. A 50mg dose recommendation has been proposed based on estimating apigenin content in clinically effective chamomile doses and popularization by Huberman.
Overall, apigenin exhibits broad therapeutic potential across anxiety, inflammation, cancer, and neurodegenerative diseases, though further human studies are needed to confirm its efficacy and safety.